BMO on Disc Medicine (IRON) Post Mgmt Call: 'management indicated that FDA has given no indication that the NDA review process is currently at risk'
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $120.00 price target on Disc Medicine (NASDAQ: IRON).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
